Brief: First Participants Dosed In Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir For Covid-19 Outbreak Control In Canadian Long-Term Care Homes

Appili Therapeutics

20/10/2020 12:29

Oct 20 (Reuters) - Appili Therapeutics Inc  APLI.TO :
    * FIRST PARTICIPANTS DOSED IN APPILI THERAPEUTICS’ PHASE 2
CLINICAL TRIAL EVALUATING FAVIPIRAVIR FOR COVID-19 OUTBREAK
CONTROL IN CANADIAN LONG-TERM CARE HOMES
    * APPILI THERAPEUTICS INC - RESEARCHERS PLAN TO ENROLL
APPROXIMATELY 760 PARTICIPANTS IN PLACEBO-CONTROLLED STUDY
    * APPILI THERAPEUTICS - EXPECTS TO REPORT TOPLINE DATA FROM
STUDY
IN 2021 FOR PHASE 2 CLINICAL TRIAL
    * APPILI- PRIMARY OUTCOME WILL BE CONTROL OF OUTBREAK,
DEFINED AS
NO NEW MICROBIOLOGICALLY CONFIRMED CASES OF COVID19 FOR ATLEAST
24 CONSECUTIVE DAYS
    * APPILI THERAPEUTICS - AN AGGREGATE OF 5.3 MILLION SHARES
AND
835,688 OPTIONS CURRENTLY HELD IN ESCROW WILL BE RELEASED ON OR
ABOUT OCT 30
    * APPILI THERAPEUTICS INC - FINAL 3.8 MILLION SHARES AND
328,715
OPTIONS WILL BE RELEASED FROM ESCROW ON OR ABOUT DEC 29

Source text for Eikon:  ID:nBwb8wmB9a 
Further company coverage:  APLI.TO 

 ((Reuters.Briefs@thomsonreuters.com;))